Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Matthew Notarianni - Head, IR Joseph Capper - CEO & Director Doug Rice - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Anthony Petrone - Mizuho Group Operator Good afternoon, and thank you for standing by. Welcome to the MIMEDX First Quarter 2025 Operating and Financial Results Conference Call.
MiMedx (MDXG) Q1 Earnings Match Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call.
MiMedx (MDXG) Q4 Earnings Meet Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
MiMedx (MDXG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
The mean of analysts' price targets for MiMedx (MDXG) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Brad Bowers - Mizuho Securities Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2024 Operating and Financial Results Conference Call.
